Abstract The major cytogenetic subgroup of lipomas is characterized by aberrations of chromosome segment 12q13-15, which recombines with a large number of other chromosomal regions. The gene HMGA2 is the main target in these aberrations. For some recurrent rearrangements, chimeric transcripts, including the 5′ part of HMGA2, have been described. The 3′ partners identified are LPP, LHFP, CMKOR1, and EBF. In addition, subsets of other benign solid tumors show aberrations of 12q13-15. Among pleomorphic adenomas of the salivary glands, where the preferred recombination partner with 12q13-15 is 9p22-24, an HMGA2/NFIB fusion gene has been reported. In the present study, two cases of lipoma with rearrangements of 9p22-24 and 12q15 were analyzed by reverse transcription polymerase chain reaction to find out if HMGA2/NFIB was also present in lipoma. An inframe fusion transcript, combining the four first exons of HMGA2 with exon 8 of NFIB, was detected in one case. It was identical to a transcript that was previously described in salivary gland adenoma and contained a stop codon shortly 3′ of the fusion point. The finding of the same fusion gene in different tumors is not unique. For example, HMGA2/LPP has been reported in lipoma, pulmonary chondroid hamartoma, and soft tissue chondroma. Since similar 9;12 translocations have been described also in rare cases of hamartoma and uterine leiomyoma, the occurrence of HMGA2/NFIB could be postulated in these tumors as well.
Introduction
Several benign solid tumor entities are characterized cytogenetically by rearrangements of the chromosome segment 12q13-15 (e.g., [3, 7-9, 11, 17] ). The fraction of tumors displaying aberrations of this segment ranges from about 60% among lipomas and chondroid hamartomas of the lung, to 30-35% of uterine leiomyomas and hemangiopericytomas and 20-25% of pleomorphic adenomas of the salivary glands and chondromas [13] . Typically, 12q13-15 recombines with a large variety of other chromosome bands through translocations, insertions, and inversions. Although almost any band may be involved, there are some cytogenetically identical changes that have been detected in several cases. These recurrent aberrations may vary from one tumor type to another. Among lipomas, the preferred rearrangement t(3;12) (q27-28;q13-15) is present in every fifth tumor, with the involvement of 12q14-15 [14] .
The gene HMGA2 (previously HMGIC), located in 12q14-15, is the central molecular target of these chromosomal aberrations and plays an essential role in the tumorigenesis of these lesions [1, 4] . The break points related to structural chromosome aberrations may be located within the gene or at megabase distances outside of the gene, and the effects may be dysregulation of gene expression, truncation of the gene, or formation of a fusion gene encoding a chimeric transcript. Among lipomas, HMGA2 has been reported to form fusion genes with CMKOR1 (in 2q35-37), LPP (in 3q27-28), EBF (in 5q33), and LHFP (in 13q12) [2, 15, 18, 19] . The HMGA2/LPP chimera has also been described in chondroid hamartomas [20] and in one case of soft tissue chondroma [3] .
Among pleomorphic adenomas of the salivary gland, the major cytogenetic subgroup is characterized by aberrations of 8q12, whereas a minor subgroup shows rearrangements of 12q13-15. The dominating aberration is t(3;8), but both 8q12 and 12q13-15 have been found to recombine with 9p22-24 in several cases. In two tumors, the recombination between 9p and 12q segments is demonstrated to result in the formation of an HMGA2/NFIB fusion gene [5] .
In the present study, two cases of lipoma with a recombination between 9p and 12q were investigated by reverse transcription polymerase chain reaction (RT-PCR) to find out whether an HMGA2/NFIB chimera may be present also in this tumor type.
Materials and methods
Two cases of lipoma with rearrangements affecting 9p22-24 and 12q15, as determined by G-band karyotyping, were available for RT-PCR analyses (Table 1) .
Culturing, harvesting, and chromosome banding of the tumor cells were as previously described [9, 10] . In brief, the tumor tissue was disaggregated mechanically and then enzymatically by 3-5 h of treatment with collagenase II. The resulting cell suspension was rinsed with a medium to remove released fats and was distributed to glass chamber slides and flasks. The RPMI 1640 medium with HEPES buffer, supplemented with 17% fetal bovine serum, Lglutamine, penicillin, and streptomycin, was then added to the cell suspension. The G-banding of the chromosomes was obtained using Wright's stain solution. Karyotypic descriptions were in accordance to "ISCN (1995). An International System for Human Cytogenetic Nomenclature" [12] .
Total ribonucleic acid (RNA) from frozen lipoma tissues kept at −80°C was isolated using the RNeasy Lipid Tissue Mini Kit (Qiagen) according to the manufacturer's instructions. From 5 μg of total RNA, complementary deoxyribonucleic acid (cDNA) was synthesized by reverse transcription in a 20-μl reaction, containing 50 mM TrisHCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, 1 mM of each dNTP, 0.5 pM random hexamers, 28 U of RNase inhibitor (RNA guard; Amersham), and 400 U of Moloney Murine Leukemia Virus reverse transcriptase (Invitrogen). The reaction mix was incubated at 37°C for 1 h, followed by 5 min at 65°C. From each case, 1 μl of cDNA was amplified by PCR. ABL1-specific primers were used as quality control [16] .
All RT-PCR reactions were carried out in final volumes of 50 μl containing 20 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.25 mM MgCl 2 , 0.2 mM of each dNTP, 1 U of PlatinumTaq polymerase (Invitrogen), 0.5 μM of each of the forward and reverse primers for HMGA2 and NFIB (Table 2) , and 1 μl of single-stranded cDNA as a template. In a second PCR with inner primers, 2 μl of the PCR product was reamplified. The PCR was run on a PCT-200 DNA Engine (MJ Research). After an initial denaturation for 5 min at 95°C, 30 amplification cycles were performed, each consisting of denaturation for 1 min at 95°C, annealing for 1 min at 60°C, and extension for 1 min at 72°C. The PCR was completed by a final extension at 72°C for 5 min.
The PCR products were analyzed on a 1.3% agarose gel, purified using the Qiagen gel extraction kit, and directly sequenced using the ABI Prism BigDye terminator version 1.1 cycle sequencing kit (Applied Biosystems) on the Applied Biosystems Model 3100-Avant DNA sequencing system. Primers used for sequencing are listed in Table 2 . For computer analyses of sequence data, the BLAST software http://www.ncbi.nlm.nih.gov/BLAST/) was used.
Results
G-banding revealed that case 1 had chromosome 12 material inserted into chromosome 9 as the sole anomaly in one clone, whereas the dominating clone had an additional copy of the derivative chromosome 9 ( Table 1 ). All three samples of the lobulated tumor of case 2 had a balanced translocation between chromosomes 9 and 12. The break points in chromosome 9 were interpreted as 9p24 and 9p22, respectively, whereas both cases had a break in 12q15.
RT-PCR products obtained with forward primers for HMGA2 (HMG846 and HMG876) and reverse primers for NFIB (NF41475-006 and NF41475-005) revealed the presence of an HMGA2/NFIB gene fusion in case 2. The size of the HMGA2/NFIB product was approximately 400 bp. Its reciprocal counterpart, NFIB/HMGA2, was not detected. The karyotype of case 2 has been published [9] The amplified products were analyzed by direct sequencing (Fig. 1) . Computer analyses of the sequence data, using the BLAST software, showed that the fusion of HMGA2/NFIB chimeric sequences was in frame and contained the first four exons of HMGA2 located 5′ to exon 8, the last coding exon of NFIB. The sixth codon of NFIB was a stop codon.
Expression of NFIB was detected in both cases, using the forward primer NF41475-001 with reverse primers NF41475-006 and NF41475-005 (Table 2 ). In addition, HMGA2 was expressed in both cases, as shown by the forward primer HMG902 combined with reverse primers HMG1037 and HMG1144, to detect transcripts from exons 1-3 and 1-5, respectively.
Discussion
In one of the two presently investigated lipomas, it was possible to demonstrate the presence of an HMGA2/NFIB fusion gene. Sequencing revealed that the resulting chimeric transcript was identical to that described previously in a case of salivary gland pleomorphic adenoma [5] (i.e., a combination of the four first exons of HMGA2 with exon 8 of NFIB). Although the fusion gene was in frame, the presence of a stop codon shortly 3′ after the fusion point was compatible with the suggestion that the important outcome of the aberration was the deregulation of the expression of the DNA-binding 5′ element of HMGA2 [1, 4, 5] . t(9;12)(p22-24;q13-15) has been reported not only in pleomorphic adenoma and lipoma but also in uterine leiomyoma and pulmonary chondroid hamartoma [6] [7] [8] . Aberrations involving 9p22-24, including t(9;12), are more common among adenomas and appear in about 9% of reported cases with chromosome aberrations, compared to <2% in the three other tumor types [13] . The fraction of tumors with t(9;12) differs less and ranges from below 1.5% among adenomas to less than 0.5% among leiomyomas. These four benign tumor types all include a cytogenetic subgroup characterized by rearrangements involving 12q13-15. Among these tumors, t(9;12)(p22-24; q13-15) has been observed in about 1% of lipomas and hamartomas, 4% of leiomyomas, and 10% of adenomas (Table 3) . Several other aberrations, including 12q13-15, are shared by two or more tumor types, but the frequencies may differ distinctly. Apart from the intrachromosomal rearrangements of chromosome 12, which are common among all four tumor types, only two segments, 9p22-24 and 14q22-24, have been involved in all of them, whereas several other rearrangements are shared by only two tumor types. With respect to the low-resolution power of chromosome banding, similar cytogenetic rearrangements need not necessarily have the same consequences at the molecular level. However, the present findings, as well as previous findings of the presence of HMGA2/LPP fusion genes in lipoma, hamartoma, and chondroma, demonstrate that at least some of these shared cytogenetic aberrations are actually identical also at the molecular level. Since one and the same fusion gene may be associated with distinctly different tumor phenotypes, it seems reasonable to suggest that the aberrant gene might affect cell proliferation in an unspecific way, rather than being a determinant of tumor cell differentiation. The differences in frequencies of certain rearrangements among tumor types could then reflect the probability of a certain aberration to occur in a certain cell type. The mechanisms behind this remain unknown.
The present study provides yet another example of genetic aberrations that are shared by different tumor types. Based on these observations and available cytogenetic data, it seems reasonable to suggest that there are more shared aberrations to be found among benign solid tumors. More specifically, an HMGA2/NFIB fusion gene might be expected to occur also among leiomyomas and hamartomas.
